EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps ( CRSwNP ) over 3 years

Patrick Huber iD, Ulrike Förster-Ruhrmann iD, Heidi Olze, Sven Becker iD, Friederike Bärhold, Mandy Cuevas, Nadine Gunder, Jan Hagemann iD, Christoph Matthias, Ludger Klimek iD, Moritz Gröger

Allergy · 2024-11 · 79 (11) · 3108-3117

DOI: 10.1111/all.16263 ↗

At a glance

Multizentrische Studie in Allergy, published online on 2024-08-07. Written by Patrick Huber and 10 co-authors. Institution: Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany. Major MEDLINE topics: Nasal Polyps, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Cited 31 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent chronic inflammatory condition affecting the nose and paranasal sinuses, posing a significant socio‐economic impact with substantial challenges in management. Biologics targeting type 2 inflammation such as dupilumab, have emerged as promising options. This study addresses a critical knowledge gap by comprehensively evaluating the 3‐year impact of sustained dupilumab therapy in CRSwNP.

Methods

A multicentric, retrospective collection of real‐world data from five tertiary referral centers in Germany was conducted, enrolling 150 adult patients. The study investigated patient‐reported outcomes, disease‐specific indices and clinical measures, focusing on therapeutic response persistence, adverse events, and factors influencing treatment continuity.

Results

Results indicate significant improvements in clinical parameters from baseline ( n = 150) with sustained effectiveness after 36 months ( n = 138) as indicated in mean score ± standard deviation. Dupilumab treatment significantly improved overall disease‐related impairment (VAS score: 7.5 ± 2.5 to 1.6 ± 1.3) and rhinosinusitis symptoms (SNOT‐22: 59.4 ± 19.4 to 18.0 ± 15.0). Nasal Polyp Scores (NPS) decreased (5.3 ± 1.8 to 0.7 ± 1.1), and olfactory function improved (3.2 ± 2.5 to 8.4 ± 2.8), with three out of four patients achieving normosmia or hyposmia after 36 months. An “Excellent” treatment response according to EUFOREA23 criteria was observed in 76.5% of patients after 36 months. Sixteen patients discontinued Dupilumab, 12 permanently. Adverse events totaled 69 in 48 patients, commonly self‐limiting.

Conclusion

The study highlights the enduring effectiveness and lack of habituation to dupilumab after a sustained therapy of 3 years, providing valuable insights into its long‐term therapeutic implications for CRSwNP patients.

Subjects

MeSH terms (MEDLINE)

Nasal PolypsSinusitisAntibodies, Monoclonal, HumanizedRhinitisHumansChronic DiseaseMaleFemaleMiddle AgedTreatment OutcomeAdultRetrospective StudiesAgedRhinosinusitis

Author keywords

CRSwNPdupilumablong‐term impactmulticentric studyreal‐word data

Substances

dupilumabAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany.
  • Department of Otorhinolaryngology, Charité-Universitätsmedizin, Berlin, Germany.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Department of Otolaryngology, Head and Neck Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Clinic and Polyclinic for Otolaryngology, University Medical Center Mainz, Mainz, Germany.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.

ORCID profiles: Patrick Huber, Ulrike Förster-Ruhrmann, Sven Becker, Jan Hagemann, Ludger Klimek

Cite

APA

Huber, P., Förster-Ruhrmann, U., Olze, H., Becker, S., Bärhold, F., Cuevas, M., Gunder, N., Hagemann, J., Matthias, C., Klimek, L., & Gröger, M. (2024). Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps ( CRSwNP ) over 3 years. Allergy, 79(11), 3108-3117. https://doi.org/10.1111/all.16263

Vancouver

Huber P, Förster-Ruhrmann U, Olze H, Becker S, Bärhold F, Cuevas M, et al. Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps ( CRSwNP ) over 3 years. Allergy. 2024;79(11):3108-3117. doi:10.1111/all.16263

BibTeX
@article{Huber2024,
  author = {Huber, Patrick and Förster-Ruhrmann, Ulrike and Olze, Heidi and Becker, Sven and Bärhold, Friederike and Cuevas, Mandy and Gunder, Nadine and Hagemann, Jan and Matthias, Christoph and Klimek, Ludger and Gröger, Moritz},
  title = {Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps ( CRSwNP ) over 3 years},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {3108--3117},
  doi = {10.1111/all.16263}
}
Start for free →